NOVARTIS logo.jpg
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
June 11, 2021 03:00 ET | Novartis Pharma AG
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal...
Trivedi Global, Inc. and Dr. William Plikerd Announce Results on the Impact of a Biofield Treated Proprietary Formulation to Combat Autoimmune and Inflammatory Disorders
May 22, 2018 16:32 ET | Trivedi Global, Inc.
Columbus, OH, USA, May 22, 2018 (GLOBE NEWSWIRE) -- Dr. William Plikerd, an evidence-based healer today announces research results on the significant impact of a proprietary biofield energy healing...
Trivedi Global, Inc. in Association with Victoria Vannes Announces Research Results on an Energy Infused Proprietary Product to Combat Inflammation and Autoimmune Disorders
May 22, 2018 13:38 ET | Trivedi Global, Inc.
Philadelphia, Pennsylvania. U.S.A., May 22, 2018 (GLOBE NEWSWIRE) -- Victoria Vannes, an evidence-based healer today announces research results on the significant impact of a proprietary biofield...